MCID: INT079
MIFTS: 51

Intrahepatic Cholangiocarcinoma

Categories: Cancer diseases, Gastrointestinal diseases, Liver diseases, Rare diseases

Aliases & Classifications for Intrahepatic Cholangiocarcinoma

MalaCards integrated aliases for Intrahepatic Cholangiocarcinoma:

Name: Intrahepatic Cholangiocarcinoma 12 20 6 15 17 71
Cholangiocarcinoma 44 71
Peripheral Intrahepatic Cholangiocarcinoma 71
Intrahepatic Bile Duct Carcinoma 12
Peripheral Cholangiocarcinoma 12

Classifications:



External Ids:

Disease Ontology 12 DOID:4928
MeSH 44 D018281
NCIt 50 C35417
SNOMED-CT 67 109842005
ICD10 32 C22.1
UMLS 71 C0206698 C0345905 C3273048

Summaries for Intrahepatic Cholangiocarcinoma

GARD : 20 Intrahepatic cholangiocarcinoma is a cancer that develops in the cells within the bile ducts; both inside and outside the liver. The terms cholangiocarinoma and bile duct cancer are often used to refer to the same condition. This condition occurs slightly more often in males than females and usually affects people who are between 50-70 years old. Signs and symptoms of intrahepatic cholangiocarcinoma include jaundice, abdominal pain, fever, weight loss, weakness and itching. Treatment options may include surgery to remove the bile duct and parts of the liver, chemotherapy and radiation.

MalaCards based summary : Intrahepatic Cholangiocarcinoma, also known as cholangiocarcinoma, is related to mucinous intrahepatic cholangiocarcinoma and sarcomatous intrahepatic cholangiocarcinoma, and has symptoms including abdominal pain and malaise. An important gene associated with Intrahepatic Cholangiocarcinoma is CCAT1 (Colon Cancer Associated Transcript 1), and among its related pathways/superpathways are mTOR signaling pathway (KEGG) and Central carbon metabolism in cancer. The drugs Celecoxib and Desflurane have been mentioned in the context of this disorder. Affiliated tissues include liver, lymph node and pancreas, and related phenotypes are Decreased shRNA abundance (Z-score < -2) and Decreased shRNA abundance (Z-score < -2)

Related Diseases for Intrahepatic Cholangiocarcinoma

Diseases related to Intrahepatic Cholangiocarcinoma via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 767)
# Related Disease Score Top Affiliating Genes
1 mucinous intrahepatic cholangiocarcinoma 32.9 KRT7 IDH1
2 sarcomatous intrahepatic cholangiocarcinoma 32.9 KRT7 KRT19 AFP
3 cholangiocarcinoma 32.4 TUG1 TP53 RASGEF1A MUC4 KRT7 KRT19
4 klatskin's tumor 32.0 TP53 KRT7 KRT19 IDH1 CPS1-IT1 AFP
5 adenocarcinoma 31.4 TP53 MUC4 KRT7 KRAS FGFR2 APC
6 bile duct adenoma 31.3 TP53 KRT7 KRT19
7 adenoma 31.2 TP53 KRT7 KRAS APC
8 cholangitis, primary sclerosing 31.1 KRT7 KRT19 AFP
9 bile duct cysts 31.0 KRT7 KRT19 KRAS AFP
10 papillary adenocarcinoma 31.0 TP53 KRT7 KRT19
11 colorectal adenocarcinoma 30.8 TP53 KRT7 KRAS APC
12 gallbladder cancer 30.7 TUG1 TP53 KRAS CCAT1
13 adenosquamous carcinoma 30.6 TP53 MUC4 KRT7 KRT19 KRAS
14 bile duct cancer 30.6 TP53 MUC4 MIR424 KRT7 KRT19 KRAS
15 bile duct cystadenocarcinoma 30.6 KRT7 AFP
16 adenofibroma 30.6 TP53 KRT7 KRT19
17 sarcomatoid carcinoma 30.6 KRT7 KRT19 KRAS
18 angiosarcoma 30.6 TP53 KRT7 KRAS
19 signet ring cell adenocarcinoma 30.5 TP53 KRT7 KRAS
20 rectum adenocarcinoma 30.5 TP53 KRT7 KRAS
21 ampulla of vater cancer 30.5 TP53 KRT7 KRAS
22 intrahepatic bile duct adenoma 30.5 TP53 KRT7 KRT19 AFP
23 mucinous adenocarcinoma 30.5 TP53 KRT7 KRT19 KRAS
24 appendix adenocarcinoma 30.5 KRT7 KRAS
25 carcinosarcoma 30.5 TP53 KRT7 KRAS
26 gastric adenocarcinoma 30.5 TP53 KRAS FGFR2 AFP
27 thyroid gland cancer 30.4 TP53 KRT7 KRT19 KRAS
28 fibrolamellar carcinoma 30.4 KRT7 KRT19 FGFR2 AFP
29 squamous cell carcinoma 30.4 TUG1 TP53 KRT7 KRT19 FGFR2 CCAT2
30 biliary tract benign neoplasm 30.3 TP53 KRT7 KRT19 KRAS AFP
31 rectum cancer 30.2 MIR424 MIR214 KRAS APC
32 bile duct disease 30.2 TP53 MIR424 KRT7 KRT19 KRAS IDH1
33 hepatoblastoma 30.2 TUG1 TP53 KRT7 KRT19 APC AFP
34 intrahepatic biliary papillomatosis 30.2 KRAS AFP
35 transverse colon cancer 30.2 KRT7 KRAS
36 skin melanoma 30.1 TP53 MIR214 KRAS IDH1
37 biliary tract disease 30.1 TP53 MIR424 KRT7 KRT19 KRAS IDH1
38 bronchiolo-alveolar adenocarcinoma 30.1 MUC4 KRT7 KRAS
39 dysgerminoma 30.1 KRT7 FGFR2 AFP
40 small intestine cancer 30.1 TP53 KRT7 KRAS
41 esophageal cancer 30.1 TP53 MUC4 KRT19 KRAS FGFR2 CCAT1
42 villous adenoma 30.1 TP53 KRT7 KRAS APC
43 thyroid gland follicular carcinoma 30.0 TP53 KRT7 KRT19 KRAS
44 gallbladder disease 30.0 TP53 KRT7 KRAS AFP
45 osteogenic sarcoma 30.0 TUG1 TP53 CCAT2 CCAT1
46 breast adenocarcinoma 30.0 TP53 KRT7 KRAS IDH1
47 endometrial cancer 29.9 TUG1 TP53 KRT7 KRAS FGFR2 CCAT1
48 brain cancer 29.9 TP53 IDH2 IDH1 APC
49 lung squamous cell carcinoma 29.8 TUG1 TP53 KRT19 KRAS FGFR2 CCAT2
50 small cell cancer of the lung 29.7 TUG1 TP53 KRT7 KRT19 CCAT2

Graphical network of the top 20 diseases related to Intrahepatic Cholangiocarcinoma:



Diseases related to Intrahepatic Cholangiocarcinoma

Symptoms & Phenotypes for Intrahepatic Cholangiocarcinoma

UMLS symptoms related to Intrahepatic Cholangiocarcinoma:


abdominal pain, malaise

GenomeRNAi Phenotypes related to Intrahepatic Cholangiocarcinoma according to GeneCards Suite gene sharing:

26 (show all 11)
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Decreased shRNA abundance (Z-score < -2) GR00366-A-114 9.4 AFP
2 Decreased shRNA abundance (Z-score < -2) GR00366-A-120 9.4 AFP
3 Decreased shRNA abundance (Z-score < -2) GR00366-A-177 9.4 APC
4 Decreased shRNA abundance (Z-score < -2) GR00366-A-29 9.4 AFP APC
5 Decreased shRNA abundance (Z-score < -2) GR00366-A-49 9.4 APC
6 Decreased shRNA abundance (Z-score < -2) GR00366-A-63 9.4 AFP
7 Decreased shRNA abundance (Z-score < -2) GR00366-A-65 9.4 AFP
8 Decreased shRNA abundance (Z-score < -2) GR00366-A-71 9.4 KRT7
9 Decreased shRNA abundance (Z-score < -2) GR00366-A-72 9.4 APC
10 Decreased shRNA abundance (Z-score < -2) GR00366-A-74 9.4 APC
11 Decreased shRNA abundance (Z-score < -2) GR00366-A-75 9.4 AFP

MGI Mouse Phenotypes related to Intrahepatic Cholangiocarcinoma:

46
# Description MGI Source Accession Score Top Affiliating Genes
1 neoplasm MP:0002006 9.17 AFP APC FGFR2 IDH2 KRAS KRT19

Drugs & Therapeutics for Intrahepatic Cholangiocarcinoma

Drugs for Intrahepatic Cholangiocarcinoma (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 272)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Celecoxib Approved, Investigational Phase 4 169590-42-5 2662
2
Desflurane Approved Phase 4 57041-67-5 42113
3
Sevoflurane Approved, Vet_approved Phase 4 28523-86-6 5206
4
Midazolam Approved, Illicit Phase 4 59467-70-8 4192
5
Meperidine Approved Phase 4 57-42-1 4058
6
Etomidate Approved Phase 4 33125-97-2 36339 667484
7 Anti-Inflammatory Agents Phase 4
8
Bilirubin Phase 4 635-65-4 5280352
9 Analgesics, Non-Narcotic Phase 4
10 Anesthetics, Inhalation Phase 4
11 Platelet Aggregation Inhibitors Phase 4
12 Cyclooxygenase 2 Inhibitors Phase 4
13 Anti-Inflammatory Agents, Non-Steroidal Phase 4
14 Cyclooxygenase Inhibitors Phase 4
15
Bismuth Phase 4 7440-69-9 16682734 105143
16 Anesthetics Phase 4
17 Omega 3 Fatty Acid Phase 4
18 Analgesics Phase 4
19 Hypnotics and Sedatives Phase 4
20 Narcotics Phase 4
21 Anesthetics, General Phase 4
22 Analgesics, Opioid Phase 4
23 Anesthetics, Intravenous Phase 4
24 Ulipristal acetate Phase 4 126784-99-4
25 Psychotropic Drugs Phase 4
26 GABA Modulators Phase 4
27 Anti-Anxiety Agents Phase 4
28
Arginine Investigational, Nutraceutical Phase 4 74-79-3 6322
29
Levoleucovorin Approved, Investigational Phase 2, Phase 3 68538-85-2 149436
30
Pembrolizumab Approved Phase 3 1374853-91-4
31
Atezolizumab Approved, Investigational Phase 3 1380723-44-3
32
nivolumab Approved Phase 3 946414-94-4
33
Ipilimumab Approved Phase 3 477202-00-9
34
Ivosidenib Approved, Investigational Phase 3 1448347-49-6 71657455
35
Gemcitabine Approved Phase 3 95058-81-4 60750
36
Capecitabine Approved, Investigational Phase 3 154361-50-9 60953
37
Citalopram Approved Phase 3 59729-33-8 2771
38
Glycine Approved, Nutraceutical, Vet_approved Phase 3 56-40-6 750
39 Calcium, Dietary Phase 2, Phase 3
40 Antibiotics, Antitubercular Phase 3
41 Anti-Bacterial Agents Phase 3
42 Hematinics Phase 3
43 Folfirinox Phase 2, Phase 3
44 Emetics Phase 3
45 Mitogens Phase 2, Phase 3
46 Tin Fluorides Phase 2, Phase 3
47 Pharmaceutical Solutions Phase 3
48 Anthelmintics Phase 3
49 Liver Extracts Phase 3
50 Hematoporphyrins Phase 3

Interventional clinical trials:

(show top 50) (show all 519)
# Name Status NCT ID Phase Drugs
1 Quality of Life in Patients With Unresectable Hilar Cholangiocarcinoma on Palliative Metallic Stent Versus Plastic Stent: A Randomized Control Trial Unknown status NCT00746538 Phase 4
2 Effect of Preoperative Biliary Drainage on Postoperative Complications in Resectable Patients With Hilar Cholangiocarcinoma(Klatskin Tumor) Unknown status NCT00797121 Phase 4
3 Effects of Different Inhalational Anesthetic Agents on the Incidence of Clinical and Subclinical Acute Kidney Injury After Liver Resection Surgery: a Pilot Study Unknown status NCT02174575 Phase 4 Sevoflurane;Desflurane
4 Prospective, Randomized, Open-label, Controlled Trial of Cyclooxygenase-2 Inhibitor (Celecoxib; Celebrex®) for Adjuvant Anticancer Effect in Patients With Biliary-pancreas Cancer. Unknown status NCT01111591 Phase 4 Cox2 inhibitor (Celecoxib)
5 Early Oral Versus Enteral Nutrition After Pancreatoduodenectomy for Periampullary Tumors: a Prospective, Randomized, Controlled Clinical Trial Unknown status NCT01642875 Phase 4
6 Efficacy and Cost Analysis of Plastic Stent Compare to Metallic Stent in Unresectable Complex Hilar Cholangiocarcinoma; a Randomized Controlled Trial Completed NCT00721175 Phase 4
7 Effects of Preoperative Immunonutrition on Infectious Complication and Th1/Th2 Differentiation in Patients Undergoing Hepatectomy Completed NCT01256047 Phase 4
8 Effects of Preoperative Immunonutrition on Infectious Complication and Th1/Th2 Differentiation in Patients Undergoing Pancreaticoduodenectomy Completed NCT01256034 Phase 4
9 Covered Versus Uncovered Metal Stents for Management of Distal Malignant Biliary Obstruction? Results of a Randomized Prospective Study. Completed NCT00280709 Phase 4
10 Pilot Study: Randomized Controlled Trial on the Influence of an Oral Nutritional Supplement Rich in Omega-3 Fatty Acids on Functional State and Quality of Life in Malnourished Patients With Gastroenterological Tumors Completed NCT00168987 Phase 4 oral nutritional supplement rich in eicosapentanoic acid
11 Etomidate With Meperidine vs Midazolam With Meperidine for Sedation During Endodscopic Retrograde Cholangiopancreatogram (ERCP) Completed NCT02027311 Phase 4 Etomidate;Midazolam;Meperidine
12 Liver Transplant Combined With Neoadjuvant Chemo-radiotherapy in the Treatment of Unresectable Hilar Cholangiocarcinoma. A Prospective Multicenter Study. Recruiting NCT04378023 Phase 4 Neoadjuvant Chemo-radiotherapy
13 Oxaliplatin Plus Gemcitabine Versus Capecitabine Alone as Adjuvant Treatment in the Prevention of Recurrence of Intrahepatic Cholangiocarcinoma Unknown status NCT02548195 Phase 3 oxaliplatin and gemcitabine;capecitabine
14 Unilateral Versus Bilateral Stents for Bismuth Type II and III Malignant Hilar Strictures: A Prospective, Multi-center Randomized Controlled Trial Unknown status NCT00653978 Phase 3
15 Clinical Trial of Adjuvant Chemotherapy Followed by Concurrent Chemoradiotherapy Compared With Adjuvant Chemotherapy Alone in Patients With Gallbladder Carcinoma and Extrahepatic Cholangiocarcinoma Unknown status NCT02798510 Phase 3 capecitabine;gemcitabine
16 Open-label Observational Study of Plastic Cylindrical Fiber Optic Diffuser (Pioneer Optics) in Photodynamic Therapy for the Management of Cholangiocarcinoma. Unknown status NCT01755013 Phase 2, Phase 3
17 A Randomized Controlled Trial Comparing Endoscopic Biliary Radiofrequency Ablation With Photodynamic Therapy for Inoperable Cholangiocarcinoma Unknown status NCT01739465 Phase 2, Phase 3
18 A Prospective, Randomized Trial of Early Enteral Feeding After Pylorus Preserving Pancreatoduodenectomy Unknown status NCT00809081 Phase 3
19 Photodynamic Therapy With S-1 in the Patients With Unresectable Type III or IV Cholangiocarcinoma: A Prospective Randomized Trial With Open Label Control Completed NCT00869635 Phase 3 S-1 Chemotherapy
20 Gemcitabine, Alone or in Combination With Cisplatin, in Patients With Advanced or Metastatic Cholangiocarcinomas and Other Biliary Tract Tumors: A Multicentre, Randomized Phase III Study Completed NCT00262769 Phase 3 cisplatin;gemcitabine hydrochloride
21 Porfimer Sodium Photodynamic Therapy Plus Stenting Versus Stenting Alone in Patients With Advanced or Metastatic Cholangiocarcinomas and Other Biliary Tract Tumours: a Multicentre, Randomised, Phase Lll Study Completed NCT00513539 Phase 3 porfimer sodium
22 Phase III Multicenter Randomized Study Comparing the Effect of Adjuvant Chemotherapy for Six Months With Gemcitabine-Oxaliplatin 85 mg/m2 (GEMOX 85) to Observation in Patients Who Underwent Surgery for Cancer of the Bile Ducts Completed NCT01313377 Phase 3 gemcitabine hydrochloride;oxaliplatin
23 A Phase III, Randomised, Multicentre Open-label Study of Active Symptom Control (ASC) Alone or ASC With Oxaliplatin/ 5F-U Chemotherapy for Patients With Locally Advanced/ Metastatic Biliary Tract Cancers Previously Treated With Cisplatin/ Gemcitabine Chemotherapy. Completed NCT01926236 Phase 3 L-folinic acid;5 FU;Oxaliplatin
24 Randomized Phase II-III Study of Chemoradiation With Fluorouracil and Cisplatin Versus Chemotherapy (Gemcitabine/Oxaliplatin) in Non Resectable But Non Metastatic Cancer of the Biliary Tract Completed NCT00304135 Phase 2, Phase 3 cisplatin;gemcitabine hydrochloride;oxaliplatin
25 A Randomised Clinical Trial Evaluating Adjuvant Chemotherapy With Capecitabine Compared to Expectant Treatment Alone (Observation) Following Surgery for Biliary Tract Cancer Completed NCT00363584 Phase 3 capecitabine
26 Randomised Phase II/III Study, Assessing the Safety and Efficacy of Modified Folfirinox Versus Gemcis in Locally Advanced, Unresectable and/or Metastatic Bile Duct Tumours Completed NCT02591030 Phase 2, Phase 3 GEMCIS;mFolfirinox
27 Hepatic Arterial Infusion Chemotherapy of Irinotecan, Oxaliplatin, 5-Fluorouracil and Leucovorin Versus Systemic Chemotherapy of Gemcitabine and Oxaliplatin for Unresectable Intrahepatic Cholangiocarcinoma Recruiting NCT03771846 Phase 3 irinotecan, oxaliplatin , fluorouracil, and leucovorin;gemcitabine and oxaliplatin
28 Adjuvant Chemotherapy With Gemcitabine and Cisplatin Compared to Standard of Care After Curative Intent Resection of Cholangiocarcinoma and Muscle Invasive Gall Bladder Carcinoma (ACTICCA-1 Trial) Recruiting NCT02170090 Phase 3 Gemcitabine;Cisplatin;Capecitabine
29 Percutaneous Bilateral Versus Unilateral Metal Stent Placement for Hilar Cholangiocarcinoma : A Prospective Open-label Randomized Controlled Trial Recruiting NCT02108145 Phase 2, Phase 3
30 A Phase 3 Multicenter, Open-Label, Randomized, Controlled Study of Oral Infigratinib Versus Gemcitabine With Cisplatin in Subjects With Advanced/Metastatic or Inoperable Cholangiocarcinoma With FGFR2 Gene Fusions/Translocations: The PROOF Trial Recruiting NCT03773302 Phase 3 BGJ398;Gemcitabine;Cisplatin
31 Adjuvant Chemotherapy With Gemcitabine and Capecitabine Compared to Capecitabine for Biliary Tract Cancer After Curative Resection Recruiting NCT03779035 Phase 3 Gemcitabine;Capecitabine
32 A Randomized Controlled, Multicenter, Open, Seamless Phase II-III Clinical Trial of PD1 Antibody (Toripalimab), Lenvatinib and GEMOX Neoadjuvant Treatment for Resectable Intrahepatic Cholangiocarcinoma With High-risk Recurrence Factors Recruiting NCT04669496 Phase 2, Phase 3 Neoadjuvant treatment
33 Bortezomib in Treating Patients With Intrahepatic Cholangiocellular Carcinoma Featuring PTEN Deficiency Recruiting NCT03345303 Phase 3 Bortezomib
34 Randomized, Controlled Study to Compare the Efficacy, Safety and Pharmacokinetics of Melphalan/HDS Treatment Given Sequentially Following Cisplatin/Gemcitabine Versus Cisplatin/Gemcitabine in Patients With IntraHepatic Cholangiocarcinoma Recruiting NCT03086993 Phase 2, Phase 3 Cisplatin and Gemcitabine
35 The Efficacy of Levamisole Hcl in Advanced Intrahepatic Cholangiocarcinoma . A Multicenter, Open, Randomized, Prospective Study Recruiting NCT03940378 Phase 3 Levamisole Hydrochloride;Anlotinib Hydrochloride Capsules
36 Phase III Randomized Trial of High Dose Chemoradiation and Systemic Chemotherapy vs Systemic Chemotherapy Alone in Patients With Unresectable Nonmetastatic Cholangiocarcinoma Recruiting NCT02773485 Phase 3 Systemic chemotherapy
37 A Phase 3, Open-Label, Randomized, Active-Controlled, Multicenter Study to Evaluate the Efficacy and Safety of Pemigatinib Versus Gemcitabine Plus Cisplatin Chemotherapy in First-Line Treatment of Participants With Unresectable or Metastatic Cholangiocarcinoma With FGFR2 Rearrangement (FIGHT-302) Recruiting NCT03656536 Phase 3 Pemigatinib;Gemcitabine;Cisplatin
38 A Phase III Randomized Trial of Gemcitabine, Cisplatin, and Nab-Paclitaxel Versus Gemcitabine and Cisplatin in Newly Diagnosed, Advanced Biliary Tract Cancers Recruiting NCT03768414 Phase 3 Cisplatin;Gemcitabine Hydrochloride;Nab-paclitaxel
39 Impact of Early Palliative Care on Overall Survival of Patients With Metastatic Upper Gastrointestinal Cancers, Treated With First-line Chemotherapy: a Randomized Phase III Trial Recruiting NCT02853474 Phase 3
40 A Randomized Non-inferiority Trial Evaluating the Length of Treatment With PD-1/PD-L1 Inhibitors in Patients With Advanced Solid Tumors Recruiting NCT04157985 Phase 3 Continue PD-1/PD-L1 Inhibitors treatment
41 A Phase II/III, Multicenter, Randomized, Placebo-controlled Study of Gemcitabine Plus Cisplatin With or Without Bintrafusp Alfa (M7824) as First-line Treatment of Biliary Tract Cancer Recruiting NCT04066491 Phase 2, Phase 3 Bintrafusp alfa;Placebo;Gemcitabine;Cisplatin
42 Phase III Study of Radiofrquency Ablation Combined With Cytokine-induced Killer Cells for the Patients With Cholangiocarcinoma Active, not recruiting NCT02482454 Phase 2, Phase 3
43 Prospective, Multicenter, Randomized, Controlled Study Evaluating SIR-Spheres Y-90 Resin Microspheres Preceding Cisplatin-gemcitabine (CIS-GEM) Chemotherapy Versus CIS-GEM Chemotherapy Alone as First-line Treatment of Patients With Unresectable Intrahepatic Cholangiocarcinoma Active, not recruiting NCT02807181 Phase 2, Phase 3 Cisplatin-gemcitabine
44 A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-controlled Study of AG-120 in Previously-treated Subjects With Nonresectable or Metastatic Cholangiocarcinoma With an IDH1 Mutation Active, not recruiting NCT02989857 Phase 3 AG-120;AG-120 matched placebo
45 A Randomized, Multicenter, Open-label, Phase 3 Study to Compare the Efficacy and Safety of GEMOX(Gemcitabine/Oxaliplatin) vs XELOX(Xeloda/Oxaliplatin) in Advanced Biliary Tract Carcinoma Active, not recruiting NCT01470443 Phase 3 Oxaliplatin;Oxaliplatin
46 A Phase 3, Open-Label, Randomized Study of Futibatinib Versus Gemcitabine-Cisplatin Chemotherapy as First-Line Treatment of Patients With Advanced Cholangiocarcinoma Harboring FGFR2 Gene Rearrangements FOENIX-CCA3 Not yet recruiting NCT04093362 Phase 3 TAS-120;Cisplatin/Gemcitabine
47 Randomized Phase III Study of Focal Radiation Therapy for Unresectable, Localized Intrahepatic Cholangiocarcinoma Terminated NCT02200042 Phase 3
48 Multicenter, Open-label, Randomized, Controlled Phase III Clinical Study of the Efficacy and Safety of Photodynamic Therapy Using Porfimer Sodium for Injection as Treatment for Unresectable Advanced Perihilar Cholangiocarcinoma Terminated NCT02082522 Phase 3 Photodynamic therapy-Photofrin;Chemotherapy regimen
49 Photodynamic Therapy for Palliation of Unresectable Cholangiocarcinoma A Multicenter, Open Label, Randomized, Controlled Phase III Trial Terminated NCT00907413 Phase 3
50 Efficiency Evaluation of Photodynamic Therapy With Photofrin® on Unresectable Type III or IV Cholangiocarcinomas - A Prospective, Multicentric and Randomized Study. Terminated NCT00540735 Phase 3

Search NIH Clinical Center for Intrahepatic Cholangiocarcinoma

Cochrane evidence based reviews: cholangiocarcinoma

Genetic Tests for Intrahepatic Cholangiocarcinoma

Anatomical Context for Intrahepatic Cholangiocarcinoma

MalaCards organs/tissues related to Intrahepatic Cholangiocarcinoma:

40
Liver, Lymph Node, Pancreas, Colon, Neutrophil, Endothelial, Thyroid

Publications for Intrahepatic Cholangiocarcinoma

Articles related to Intrahepatic Cholangiocarcinoma:

(show top 50) (show all 13057)
# Title Authors PMID Year
1
MicroRNA profiling of human intrahepatic cholangiocarcinoma cell lines reveals biliary epithelial cell-specific microRNAs. 47 61
19755794 2009
2
Development and validation of a CpG island methylator phenotype-related prognostic signature for cholangiocarcinoma. 61
32996133 2021
3
Vascular liver injury mimicking an intrahepatic cholangiocarcinoma in a COVID-19 patient. 61
33458846 2021
4
Prognosis and Circumferential Margin in Patients with Resected Hilar Cholangiocarcinoma. 61
32914390 2021
5
Enhanced oral bioavailability and biodistribution of atractylodin encapsulated in PLGA nanoparticle in cholangiocarcinoma. 61
33125766 2021
6
Expression of integrin ανβ6 differentiates perihilar cholangiocarcinoma (PHC) from benign disease mimicking PHC. 61
33069505 2021
7
Eligibility for Liver Transplantation in Patients with Perihilar Cholangiocarcinoma. 61
32901308 2021
8
A Study on Radial Margin Status in Resected Perihilar Cholangiocarcinoma. 61
30946074 2021
9
Use of preoperative controlling nutritional status (CONUT) score as a better prognostic marker for distal cholangiocarcinoma after pancreatoduodenectomy. 61
32761459 2021
10
LHPP suppresses tumorigenesis of intrahepatic cholangiocarcinoma by inhibiting the TGFβ/smad signaling pathway. 61
33401010 2021
11
Immunotherapy in cholangiocarcinoma. 61
33507028 2021
12
A potential role for aspirin in the prevention and treatment of cholangiocarcinoma. 61
32997790 2021
13
PET/MRI of the hepatobiliary system: Review of techniques and applications. 61
33285404 2021
14
Cholangiocarcinoma miscoding in hepatobiliary centres. 61
33032867 2021
15
Notch activity characterizes a common hepatocellular carcinoma subtype with unique molecular and clinicopathologic features. 61
33038431 2021
16
Role of real-time shear-wave elastogarphy in differentiating hepatocellular carcinoma from other hepatic focal lesions. 61
32345847 2021
17
MDSCs in liver cancer: A critical tumor-promoting player and a potential therapeutic target. 61
33508529 2021
18
The prognostic value of sarcopenia combined with hepatolithiasis in intrahepatic cholangiocarcinoma patients after surgery: A prospective cohort study. 61
32933804 2021
19
Evaluation of Primary Liver Cancers Using Hepatocyte-Specific Contrast-Enhanced MRI: Pitfalls and Potential Tips. 61
32700807 2021
20
BAP1 promotes viability and migration of ECA109 cells through KLF5/CyclinD1/FGF-BP1. 61
33529461 2021
21
Roles and mechanisms of BAP1 deubiquitinase in tumor suppression. 61
33462414 2021
22
Identification of tumors with NRG1 rearrangement, including a novel putative pathogenic UNC5D-NRG1 gene fusion in prostate cancer by data-drilling a de-identified tumor database. 61
33583086 2021
23
High expression of tissue O-linked glycans is associated with a malignant phenotype of cholangiocarcinoma. 61
33535865 2021
24
Assessment of the Outcomes of Intrahepatic Cholangiocarcinoma After Ultrasound-Guided Percutaneous Microwave Ablation Based on Albumin-Bilirubin Grade. 61
33057809 2021
25
Nerve fibers in the tumor microenvironment in neurotropic cancer-pancreatic cancer and cholangiocarcinoma. 61
33288884 2021
26
De novo Colorectal and Pancreatic Cancer in Liver Transplant Recipients: Identifying the Higher Risk Populations. 61
33544906 2021
27
Utility of palliative EUS-guided biliary drainage using lumen-apposing metal stents: a prospective multicenter feasibility study (with video). 61
33545136 2021
28
Conversion therapy for intrahepatic cholangiocarcinoma and tumor downsizing to increase resection rates: A systematic review. 61
32622478 2021
29
Developing models of cholangiocarcinoma to close the translational gap in cancer research. 61
33513027 2021
30
Clinical outcomes of systemic therapy in patients with unresectable or metastatic combined hepatocellular-cholangiocarcinoma. 61
33548073 2021
31
Higher content of microcystin-leucine-arginine promotes the survival of intrahepatic cholangiocarcinoma cells via regulating SET resulting in the poorer prognosis of patients. 61
33241617 2021
32
Inter-observer agreement of computed tomography and magnetic resonance imaging on gross tumor volume delineation of intrahepatic cholangiocarcinoma: an initial study. 61
33532258 2021
33
The tireless search to improve the prognostic assessment of intrahepatic cholangiocarcinoma: An urgent need. 61
33464725 2021
34
Time to Rethink Upfront Surgery for Resectable Intrahepatic Cholangiocarcinoma? Implications from the Neoadjuvant Experience. 61
33586068 2021
35
A case series of hilar cholangiocarcinoma: A single surgeon experience over 20-years. 61
33537137 2021
36
Targeting the tumor microenvironment in cholangiocarcinoma: implications for therapy. 61
33502260 2021
37
Potential Benefits of Holmium-166 Radioembolization as a Neoadjuvant Treatment of Intrahepatic Cholangiocarcinoma. 61
33090248 2021
38
Anatomical Basis of Routine Caudate Lobe Resections in Hilar Cholangiocarcinoma. 61
33547586 2021
39
Implication of CD69+ CD103+ Tissue-resident-like CD8+ T cells as a Potential Immunotherapeutic Target for Cholangiocarcinoma. 61
33548061 2021
40
First Case of Full Robotic ALPPS for Intrahepatic Cholangiocarcinoma. 61
32638168 2021
41
Reassessing the role of surgery in the elderly or chronically sick with proximal extrahepatic cholangiocarcinoma. 61
33087251 2021
42
Clinical correlation of cadherin-17 marker with advanced tumor stages and poor prognosis of cholangiocarcinoma. 61
33524213 2021
43
Key challenges for drugs in clinical development for cholangiocarcinoma. 61
33530767 2021
44
Significance of HMGA2 expression as independent poor prognostic marker in perihilar and distal cholangiocarcinoma resected with curative intent. 61
32878723 2021
45
A case of juvenile eosinophilic cholangitis: Rapid peripheral blood hypereosinophilia after admission leading to diagnosis. 61
33553674 2021
46
LncRNA MT1JP plays a protective role in intrahepatic cholangiocarcinoma by regulating miR-18a-5p/FBP1 axis. 61
33557774 2021
47
Difficulty in differentiating between IgG4-related hepatic inflammatory pseudotumor and intrahepatic cholangiocarcinoma. 61
33037585 2021
48
Detection of Tumor Multifocality in Resectable Intrahepatic Cholangiocarcinoma: Defining the Optimal Pre-operative Imaging Modality. 61
33565011 2021
49
Long Non-coding RNA FOXD2-AS1 Promotes Proliferation, Migration, and Invasion in Cholangiocarcinoma Through Regulating miR-760/E2F3 Axis. 61
33570683 2021
50
SP1 induced long non-coding RNA AGAP2-AS1 promotes cholangiocarcinoma proliferation via silencing of CDKN1A. 61
33522895 2021

Variations for Intrahepatic Cholangiocarcinoma

ClinVar genetic disease variations for Intrahepatic Cholangiocarcinoma:

6
# Gene Name Type Significance ClinVarId dbSNP ID GRCh37 Pos GRCh38 Pos
1 APC NM_000038.6(APC):c.4440G>C (p.Gln1480His) SNV Uncertain significance 482375 rs876659881 5:112175731-112175731 5:112840034-112840034
2 APC NM_000038.6(APC):c.8461G>A (p.Asp2821Asn) SNV Uncertain significance 559959 rs1554089164 5:112179752-112179752 5:112844055-112844055
3 APC NM_000038.6(APC):c.8332G>T (p.Ala2778Ser) SNV Uncertain significance 133537 rs587778046 5:112179623-112179623 5:112843926-112843926

Expression for Intrahepatic Cholangiocarcinoma

Search GEO for disease gene expression data for Intrahepatic Cholangiocarcinoma.

Pathways for Intrahepatic Cholangiocarcinoma

Pathways related to Intrahepatic Cholangiocarcinoma according to GeneCards Suite gene sharing:

# Super pathways Score Top Affiliating Genes
1
Show member pathways
11.93 TP53 KRAS FGFR2 APC
2 10.87 TP53 KRAS IDH2 IDH1 FGFR2
3
Show member pathways
10.07 IDH2 IDH1

GO Terms for Intrahepatic Cholangiocarcinoma

Biological processes related to Intrahepatic Cholangiocarcinoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 NADP metabolic process GO:0006739 9.16 IDH2 IDH1
2 isocitrate metabolic process GO:0006102 8.96 IDH2 IDH1
3 glyoxylate cycle GO:0006097 8.62 IDH2 IDH1

Molecular functions related to Intrahepatic Cholangiocarcinoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 isocitrate dehydrogenase (NADP+) activity GO:0004450 8.96 IDH2 IDH1
2 isocitrate dehydrogenase activity GO:0004448 8.62 IDH2 IDH1

Sources for Intrahepatic Cholangiocarcinoma

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
20 GARD
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
53 NINDS
54 Novoseek
56 OMIM via Orphanet
57 OMIM® (Updated 05-Mar-2021)
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 TGDB
70 Tocris
71 UMLS
72 UMLS via Orphanet
Content
Loading form....